The novel microtubule-interfering agent TZT-1027 enhances the anticancer effect of radiation in vitro and in vivo (Q36609596)

15 August 2017

The novel microtubule-interfering agent TZT-1027 enhances the anticancer effect of radiation in vitro and in vivo (English)

1 reference

15 August 2017

Y Akashi

1

1 reference

15 August 2017

I Okamoto

2

1 reference

15 August 2017

M Suzuki

3

1 reference

15 August 2017

K Tamura

4

1 reference

15 August 2017

T Iwasa

5

1 reference

15 August 2017

S Hisada

6

1 reference

15 August 2017

T Satoh

7

1 reference

15 August 2017

K Nakagawa

8

1 reference

15 August 2017

K Ono

9

1 reference

15 August 2017

M Fukuoka

10

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 May 2007

1 reference

British Journal of Cancer

15 August 2017

1 reference

15 August 2017

96

1 reference

15 August 2017

10

1 reference

15 August 2017

1532-1539

1 reference

Antivascular effects of TZT-1027 (Soblidotin) on murine Colon26 adenocarcinoma

15 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2359952

Antitumor activity of TZT-1027 (Soblidotin).

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2359952

Cell cycle effects of vinflunine, the most recent promising Vinca alkaloid, and its interaction with radiation, in vitro

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2359952

Phase I and pharmacokinetic study of the dolastatin 10 analogue TZT-1027, given on days 1 and 8 of a 3-week cycle in patients with advanced solid tumors

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2359952

Patupilone acts as radiosensitizing agent in multidrug-resistant cancer cells in vitro and in vivo.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2359952

Role of cell cycle in mediating sensitivity to radiotherapy

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2359952

Epothilones: mechanism of action and biologic activity

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2359952

Microtubules as a target for anticancer drugs

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2359952

Vascular targeting agents as cancer therapeutics

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2359952

Potential radiation-sensitizing effect of semisynthetic epothilone B in human lung cancer cells

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2359952

Microtubules, microtubule-interfering agents and apoptosis.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2359952

Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2359952

Enhancement of radiation therapy by the novel vascular targeting agent ZD6126.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2359952

The role of apoptosis in 2',2'-difluoro-2'-deoxycytidine (gemcitabine)-mediated radiosensitization.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2359952

Dual G1 and G2/M phase inhibition by SC-alpha alpha delta 9, a combinatorially derived Cdc25 phosphatase inhibitor

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2359952

Screening of cell cycle inhibitors from microbial metabolites by a bioassay using a mouse cdc2 mutant cell line, tsFT210.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2359952

Combined-modality therapy for advanced non-small cell lung cancer: paclitaxel and thoracic irradiation.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2359952

Potentiation of radiation therapy by vinorelbine (Navelbine) in non-small cell lung cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2359952

Cyclic x-ray responses in mammalian cells in vitro

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2359952

Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2359952

Antitumor activity of TZT-1027, a novel dolastatin 10 derivative

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2359952

The vascular disrupting agent ZD6126 shows increased antitumor efficacy and enhanced radiation response in large, advanced tumors.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2359952

Combination of the vascular targeting agent ZD6126 with boron neutron capture therapy

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2359952

Antitumor activity of TZT-1027 (Soblidotin) against vascular endothelial growth factor-secreting human lung cancer in vivo

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2359952

The novel taxane analogs, BMS-184476 and BMS-188797, potentiate the effects of radiation therapy in vitro and in vivo against human lung cancer cells

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2359952

Induction of apoptosis in human cancer cells by TZT-1027, an antimicrotubule agent.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2359952

TZT-1027, an antimicrotubule agent, attacks tumor vasculature and induces tumor cell death.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2359952

Characterization of the interaction of TZT-1027, a potent antitumor agent, with tubulin.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2359952

Targeting the tumor vasculature with combretastatin A-4 disodium phosphate: effects on radiation therapy.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2359952

A phase I study of intravenous TZT-1027 administered on day 1 and day 8 of a three-weekly cycle in combination with carboplatin given on day 1 alone in patients with advanced solid tumours

20 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038/SJ.BJC.6603769

Phase I and pharmacokinetic study of TZT-1027, a novel synthetic dolastatin 10 derivative, administered as a 1-hour intravenous infusion every 3 weeks in patients with advanced refractory cancer

21 January 2018

1 reference

12 December 2020

Vascular targeting effects of ZD6126 in a C3H mouse mammary carcinoma and the enhancement of radiation response

1 reference

12 December 2020

X-ray sensitivity during the cell generation cycle of cultured Chinese hamster cells

1 reference

12 December 2020

In vitro studies of Taxol as a radiation sensitizer in human tumor cells

1 reference

12 December 2020

Synthesis and antitumor activity of novel dolastatin 10 analogs

1 reference

12 December 2020

Vinorelbine (Navelbine), cisplatin, and concomitant radiation therapy for advanced malignancies of the chest: a Phase I study

1 reference

12 December 2020

Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature

1 reference

12 December 2020

Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, which was administered to patients with advanced solid tumors on days 1 and 8 in 3-week courses

1 reference

12 December 2020

Combination effect of TZT-1027 (Soblidotin) with other anticancer drugs

1 reference

12 December 2020

Accuracy, feasibility, and clinical impact of prospective Bayesian pharmacokinetically guided dosing of cyclophosphamide, thiotepa, and carboplatin in high-dose chemotherapy

1 reference

Crossref

https://api.crossref.org/works/10.1038/SJ.BJC.6603769

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1038/SJ.BJC.6603769

1 reference

15 August 2017

1 reference

15 August 2017

PubMed publication ID

17473826

1 reference